Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer

Although oncogenic KRAS represents a therapeutically relevant target in pancreatic cancer, it is deemed “non-druggable” because of the intrinsic difficulty in designing direct inhibitors of KRAS. Our recent work demonstrated a KRAS-integrin-linked kinase (ILK) regulatory feedback loop that allows pa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Small GTPases
Autores principales: Chu, Po-Chen, Kulp, Samuel K., Bekaii-Saab, Tanios, Chen, Ching-Shih
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2016
Materias:
Commentary - Commissioned
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6204986/
https://ncbi.nlm.nih.gov/pubmed/27936345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21541248.2016.1251383
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares